BST1 and major depressive disorder: The difference in the effective doses of selegiline between the respective genotypes might arise from changes in monoaminergic dysfunction and/or expression of depression- and anxiety-associated proteins in CD157 KO mice, suggesting that an effective dose of selegiline for the treatment of depression in PD may be lower than that in major depression.